Perkin-Elmer Eyes the Value Chain
Executive Summary
Perkin-Elmer built the machines that enabled the boom in genomics research--automated DNA sequencers. Genomics companies have done well, but Perkin-Elmer hasn't. The company is prepared to spend up to $1 billion over the next several years on external collaborations and acquisitions in an effort to climb the value chain and capture high-value applications of its tools for itself.